XOMA Halts Study By: MarketMinute.com Stock News March 05, 2014 at 16:25 PM EST XOMA Corp. (Nasdaq: XOMA) will stop testing its arthritis treatment gevokizumab after it failed two mid-stage studies sending the stock price plummeting $2.62 to close at $6.82.